drugset / Trial / NCT03787680
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the effectiveness (how well the drugs work), safety, and tolerability of the investigational drug combination of olaparib and AZD6738 for all patients with metastatic castration-resistant prostate cancer.
Timeline
- Start
- 2019-10-31
- Primary completion
- 2023-01-26
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceralasertib | Small molecule | 160 mg | Oral |
| Subject | Olaparib | Small molecule | 300 mg | Oral |